Introduction: This prospective observational study aimed to investigate the incidence
| INTRODUCTION
Balloon-based catheter ablation has been recently developed as an alternative to radiofrequency catheter ablation in the treatment of atrial fibrillation (AF). 1 Balloon-based AF ablation, as well as radiofrequency catheter-based AF ablation, has a potential risk for periprocedural embolic complications. Symptomatic embolisms, including ischemic strokes, transient ischemic attacks (TIAs), and systemic emboli, after cryoballoon ablation (CBA) of AF are rare occurrences, while silent cerebral emboli detected by brain magnetic resonance (MR) imaging are relatively common, and have been reported to be observed in 4.3% to 50% of patients undergoing CBA. [2] [3] [4] [5] [6] [7] [8] [9] [10] So far, limited data are available on the incidence of symptomatic and silent embolisms after radiofrequency HotBalloon ablation (HBA) of AF.
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Adequate periprocedural anticoagulation using oral anticoagulants plays an important role in preventing thromboembolic complications associated with AF ablation. 12, 13 The majority of the previous studies with brain MR imaging after CBA consisted of patients receiving periprocedural oral anticoagulation with warfarin, while a few studies [8] [9] [10] included some patients with direct oral anticoagulants (DOACs) in addition to those with warfarin.
The purpose of this prospective observational study was to investigate the incidence of symptomatic and silent cerebral embolisms after balloon-based AF ablation among patients receiving periprocedural DOAC treatment and compare that between CBA and HBA.
2 | METHODS
| Study population
This study prospectively enrolled 123 consecutive patients who underwent an initial balloon-based catheter ablation of paroxysmal or persistent AF with periprocedural DOAC treatment and brain MR imaging on the next day after the ablation procedure at Gunma Prefectural Cardiovascular Center from December 2014 to July 2018. The exclusion criteria from this study were an age of less than 20 years, long-standing persistent AF with a duration of more than one year, oral anticoagulation with warfarin, presence of any intracardiac thrombi, any prosthetic heart valve, rheumatic mitral valve disease, and absolute and relative contraindications to MR imaging including the presence of metallic implants and severe claustrophobia. All patients underwent transesophageal echocardiography to rule out any intracardiac thrombi on the day of the ablation procedure or the day before. The study protocol was approved by the local ethics committee and all patients provided written informed consent for participation.
| Periprocedural anticoagulation
All patients received oral anticoagulation with the standard or reduced DOAC dosage approved in Japan: dabigatran at a dose of 110 or 150 mg twice daily, rivaroxaban at 10 or 15 mg once daily in the morning, apixaban at 2.5 or 5 mg twice daily, or edoxaban at 30 or 60 mg once daily in the morning. The DOACs were continued throughout the periprocedural period, or discontinued only on the day of the procedure and reinitiated on the next morning after the procedure. Neither low molecular weight heparin nor unfractionated heparin was administered before the procedure.
Immediately after the femoral venous puncture during the procedure, an initial heparin bolus of 10 000 units was given intravenously, followed by a continuous and additional bolus heparin infusion to maintain an activated clotting time (ACT) between 300 and 400 seconds. The ACT was measured every 10 minutes until the ACT value reached 300 seconds and thereafter every 10 to 30 minutes. The intravenous heparin administration was once stopped at the end of the procedure and protamine was given to partially reverse the anticoagulation effect of heparin at the operators' discretion. After achieving hemostasis of the femoral venous puncture sites and verifying the absence of any pericardial effusions by echocardiography, all patients received a continuous heparin infusion at a dose of 10 000 units per 24 hours until the DOACs were administered on the next morning after the procedure.
| Balloon-based catheter ablation
Deep conscious sedation was maintained throughout the procedure using propofol or dexmedetomidine, and pentazocine. The ostia and To detect any right phrenic nerve injury during balloon ablation of the right-sided PVs, the right phrenic nerve was constantly paced from the SVC and the fluoroscopic diaphragm movement during spontaneous breathing was monitored. The esophageal temperature was monitored using an esophageal temperature probe to prevent any esophageal injury. 
| Cryoballoon ablation

| Postablation embolic and hemorrhagic events
Neurological assessments were performed before and after the procedure. Postablation embolic events consisted of (1) symptomatic embolisms, including ischemic strokes, TIAs, and systemic emboli and (2) SCILs, which resulted in neither apparent neurological deficits nor symptoms and were detected by MR imaging. The incidence of bleeding events was also evaluated. Major bleeding was defined as cardiac tamponade or pericardial effusions requiring drainage, intracranial, and gastrointestinal hemorrhages, a hemothorax, retroperitoneal bleeding, any bleeding requiring a blood transfusion, and vascular access site complications requiring any intervention. Minor bleeding events were defined as bleeding other than major bleeding events.
| Statistical analysis
Continuous variables were expressed as the mean ± standard deviation, and categorical variables were as the number and percentage of patients. A comparative analysis between the CBA and HBA groups was performed using a Student or Welch t test for continuous variables, and a χ 2 or Fisher exact test for categorical variables. A multivariate logistic regression model was estimated to identify any significant predictors of SCILs using potential confounders with a clinical significance or significance association with P < 0.1 in the univariate analyses. P < 0.05 was considered statistically significant. The statistical analyses were carried out using SPSS Statistics 22 Software (SPSS, Inc, Chicago, IL).
| RESULTS
The baseline and procedural characteristics of the study population are summarized in Tables 1 and 2 . The CBA and HBA groups included 65 and 58 patients, respectively. The DOACs were continued in 62 patients (CBA group, n = 32; HBA group, n = 30) throughout the periprocedural period, and discontinued in 61 (CBA group, n = 33;
HBA group, n = 28) only on the procedural day (P = 0.782). The CBA group had a significantly lower percentage of patients with hypertension, touch-up ablation for the remaining gaps after the balloon-based PVI, and protamine use after the procedure, and lower left ventricular ejection fraction than the HBA group (all P < 0.05).
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| Postablation embolic and hemorrhagic events
No symptomatic embolisms or deaths occurred in this series. Brain MR imaging was performed 23 ± 4 hours after the procedure. SCILs were detected on DWI in a total of 22 patients (17.9%), and the incidence of SCILs did not significantly differ between the CBA and HBA groups (21.5 vs 13.8%; P = 0.263) ( Table 3 and Figure 1 ).
The baseline and procedural characteristics were compared between the patients with and without SCILs ( Table 4 ). The patients with SCILs had a significantly older age than those without (P = 0.011). In a multivariate logistic regression analysis using the age, left atrial diameter, type of balloon catheters, and periprocedural continuation or discontinuation of the DOACs, an older age was an independent positive predictor of SCILs (odds ratio, 1.062; 95% confidence interval, 1.001-1.126; P = 0.046), and neither the balloon catheter type (CB or HB) nor periprocedural continuation or discontinuation of the DOACs were significant predictors (Table 5 ).
In addition, the incidence of SCILs did not significantly differ between the patients with touch-up ablation using an irrigated radiofrequency ablation catheter and those without in each group (CBA group, 15.4 vs 23.1%, P = 0.428; HBA group, 9.1 vs 16.7%,
T A B L E 1 Demographics and baseline characteristics of the study population Abbreviations: APTT, activated partial thromboplastin time; BNP, B-type natriuretic peptide; CBA, cryoballoon ablation; CHADS 2 score, congestive heart failure, hypertension, an age ≥ 75 y, diabetes mellitus (1 point for the presence of each), and a stroke and transient ischemic attack (2 points); CHA 2 DS 2 -VASc score, congestive heart failure, hypertension, diabetes mellitus, vascular disease (myocardial infarction, aortic plaque, and peripheral vascular disease), an age of 65-74 y, a female gender (1 point for the presence of each), an age ≥ 75 y, and a stroke and transient ischemic attack (2 points); DOAC, direct oral anticoagulant; HBA, HotBalloon ablation. Data are given as the mean ± SD or number (%). *The APTT was measured after the administration of the DOACs on the day before the procedure.
The CBA and HBA groups included 16 and 10 SCILs, respectively, and had a similar maximum diameter of the SCILs (4.6 ± 2.1 vs The CBA group had one major bleeding event involving a cardiac tamponade requiring a surgical repair, while the HBA group had no major bleeding event. The incidence of major and minor bleeding events was 1.5% and 7.7% in the CBA group and 0% and 5.2% in the HBA group, respectively, and was comparable between the two groups (P = 0.528 and 0.424) ( Table 3 and Figure 1 ).
| DISCUSSION
This was a prospective observational study to describe the incidence of symptomatic and silent cerebral embolisms after balloon-based catheter ablation of AF among patients receiving periprocedural oral anticoagulation with DOACs. In the current study, both CBA and HBA exhibited a similar risk of postablation cerebral embolisms. Further, an older age was only an independent positive predictor of SCILs detected by MR imaging after balloon-based AF ablation, but neither the balloon catheter type nor periprocedural oral anticoagulation protocols with the DOACs had a significant correlation with the occurrence of SCILs.
The incidence of SCILs in the CBA and HBA groups was 21.5% and 13.8%, respectively, and that in the CBA group was similar to that reported in recent studies with a CB-based AF ablation. [8] [9] [10] To the best of our knowledge, there have been no previous studies reporting the incidence of silent cerebral embolisms after radiofrequency HBA of AF. In the current study, the incidence of SCILs in the HBA group was 7.7% lower than that in the CBA group, but the absolute difference between the two groups was not statistically significant (P = 0.263). This study was exploratory and did not have Abbreviations: ACT, activated clotting time; APTT, activated partial thromboplastin time; BNP, B-type natriuretic peptide; CHADS 2 score, congestive heart failure, hypertension, an age ≥ 75 y, diabetes mellitus (1 point for the presence of each), and a stroke and transient ischemic attack (2 points); CHA 2 DS 2 -VASc score, congestive heart failure, hypertension, diabetes mellitus, vascular disease (myocardial infarction, aortic plaque, and peripheral vascular disease), an age of 65-74 y, a female gender (1 point for the presence of each), an age ≥ 75 y, and a stroke and transient ischemic attack (2 points); DOAC, direct oral anticoagulant; PVI, pulmonary vein isolation; SCILs, silent cerebral ischemic lesions. Data are given as the mean ± SD or number (%). *The APTT was measured after the administration of the DOACs on the day before the procedure.
sufficient statistical power to truly detect a difference between the two balloon catheter technologies. Further understanding of the difference in the incidence of SCILs will require an investigation in a randomized study with a larger number of patients in the future.
The occurrence of embolic events during the periprocedural period of AF catheter ablation is associated with various factors: preexisting microthrombi loosened by catheter manipulation, which were undetectable on pre-ablation transesophageal echocardiography; clots or char formation by thermal denaturation of blood proteins; intraprocedural thrombus formation on the catheters, guidewires, and sheaths; air emboli secondary to insertion of catheters into transseptal sheaths; and postablation thrombus formation due to endothelial denudation. 15, 16 Cryoenergy ablation is theoretically unlikely to cause clots or char formation. In a preclinical study by Khairy et al, 17 The patients enrolled in our study were not matched in the two techniques using the propensity score, and the CBA procedure or periprocedural anticoagulation used in that previous study was different from ours.
Yokoyama et al 18 demonstrated that thrombus formation at the electrode-tissue interface correlated highly with an interface temperature of more than 80°C during radiofrequency energy ablation.
During HBA, the central temperature of the balloon is usually set around 70°C, and the temperature of the tissue surface in contact with the balloon is maintained at 60 to 65°C, because the temperature difference between the surface and the center of the balloon is approximately 10°C. 19 Therefore, HBA is theoretically associated with a low likelihood of the occurrence of thromboembolisms. Nevertheless, our study demonstrated that SCILs after HBA
were not rare occurrences, and were observed in 13.8% of patients undergoing HBA. The occurrence of SCILs after CB-and HB-based AF ablation may be associated with air emboli, preexisting microthrombi, and intraprocedural thrombus formation on the catheters, guidewires, and sheaths rather than clots or char formation.
| Predictors of SCILs after balloon-based AF ablation
A multivariate regression analysis revealed that an older age was independently associated with a risk of SCILs. This result was consistent with that of previous studies with radiofrequency catheter ablation or CBA of AF with periprocedural oral anticoagulation using warfarin.
3,20,21 F I G U R E 2 Brain magnetic resonance (MR) imaging for silent cerebral ischemic lesions (SCILs) in two representative cases. The left panels show the diffusion-weighted MR imaging (DWI) on the day after the ablation procedure, and the right panels show the follow-up fluid-attenuated inversion recovery (FLAIR) imaging of the SCILs. One patient had a DWI-positive SCIL in the right occipital lobe (A), which was also depicted as a hyperintensity on the FLAIR imaging 36 days after the procedure (B). The other patient had a DWI-positive SCIL in the left parietal lobe (C), which was undetectable on the FLAIR imaging 34 days after the procedure (D). The lesions on the MR imaging are indicated by the arrows
